« Layoffs and Personal Finance |
| Zafgen's Epoxide Clears A Hurdle »
November 14, 2013
Nasty Odor as a Drug Side Effect
If you read the publications on the GSK compound (darapladib) that just failed in Phase III, you may notice something odd. These mention "odor" as a side effect in the clinical trial subjects. Say what?
If you look at the structure, there's a para-fluorobenzyl thioether in there, and I've heard that this is apparently not oxidized in vivo (a common fate for sulfides). That sends potentially smelly parent compound (and other metabolites?) into general circulation, where it can exit in urine and feces and even show up in things like sweat and breath. Off the top of my head, I can't think of another modern drug that has a severe odor liability. Anyone have examples?
Update: plenty of examples in the comments!
+ TrackBacks (0) | Category: Cardiovascular Disease | Clinical Trials | Pharmacokinetics
POST A COMMENT
- RELATED ENTRIES
- Targacept Fumbles the Bad News on Alzheimer's
- Modifying Red Blood Cells As Carriers
- How to Run a Drug Project: Are There Any Rules at All?
- Employment Among New Chemistry PhDs
- My Imaginary Friends Would Be Glad to Serve as Referees
- Biopharma Stock Events for the Rest of the Year
- A Drug Candidate from NCATS
- No Scripps/USC